GlassScriptPhysician profile
Mohsen Tabrizi
NPI 1093973760
$6,810.15
in general payments reported to CMS, 2019-2025
41 companies · $1,078 in 2025
The $1,078 reported for 2025 was more than what a typical Endocrinology, Diabetes & Metabolism provider received nationally (typical 2025 total: $506).
See the full distribution for Endocrinology, Diabetes & Metabolism
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,033 · 2020: $849 · 2021: $919 · 2022: $826 · 2023: $1,027 · 2024: $1,079 · 2025: $1,078.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,184.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,183.80 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lilly USA, LLC | $1,599.95 | 2019-2025 | Jardiance, Mounjaro, Trulicity |
| Novo Nordisk INC | $646.62 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Mannkind Corporation | $582.06 | 2019-2024 | Afrezza |
| Abbott Laboratories | $573.72 | 2019-2025 | Freestyle Libre 3 |
| Dexcom, INC. | $567.46 | 2022-2025 | Dexcom G6 Transmitter |
| Amarin Pharma, INC. | $254.46 | 2019-2021 | |
| Sanofi-Aventis U.S. LLC | $249.28 | 2019-2025 | |
| Amgen INC. | $215.91 | 2020-2025 | Tepezza, Evenity |
| Lifescan, INC. | $192.24 | 2019-2022 | |
| Radius Health, INC. | $155.24 | 2019-2025 | Tymlos |
| Ascensia Diabetes Care US INC. | $148.50 | 2021-2025 | |
| Abbvie INC. | $142.99 | 2021-2025 | Synthroid |
| Tandem Diabetes Care, INC. | $135.05 | 2024-2025 | T:Slim X2 Insulin Pump With Control-Iq |
| Corcept Therapeutics | $128.89 | 2020-2024 | Korlym |
| Astrazeneca Pharmaceuticals LP | $116.89 | 2020-2022 |
Show all 41 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Recordati_rare_diseases_inc. | $109.25 | 2021-2025 | Isturisa, Signifor Lar |
| Insulet Corporation | $99.10 | 2021-2025 | Omnipod |
| Xeris Pharmaceuticals, INC. | $96.54 | 2021-2025 | Recorlev |
| Becton, Dickinson and Company | $90.78 | 2019-2022 | |
| Medtronic, INC. | $65.54 | 2021-2024 | Minimed 780g |
| Cequr Corporation | $64.40 | 2023-2024 | Cequr Simplicity |
| Alvogen INC | $54.60 | 2023 | Teriparatide |
| Madrigal Pharmaceuticals | $54.42 | 2024-2025 | Resmetirom, Rezdiffra |
| Zealand Pharma US, INC. | $45.58 | 2021 | |
| Antares Pharma, INC. | $44.76 | 2019-2021 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $41.99 | 2019-2025 | Jardiance |
| Ibsa Pharma INC. | $30.09 | 2019-2020 | |
| Medtronic Minimed, INC. | $29.52 | 2020 | |
| Ionis Pharmaceuticals, INC. | $29.01 | 2025 | Tryngolza |
| Beta Bionics, INC. | $26.21 | 2023 | Ilet Bionic Pancreas |
| Alexion Pharmaceuticals, INC. | $23.58 | 2019 | |
| Esperion Therapeutics, INC. | $22.91 | 2021 | |
| Merck Sharp & Dohme LLC | $22.00 | 2020 | |
| Bigfoot Biomedical INC | $21.61 | 2021 | |
| Nevro Corp. | $20.91 | 2022 | |
| Acella Pharmaceuticals, LLC | $19.17 | 2025 | NP Thyroid 60 |
| Amryt Pharma Holdings LTD | $18.68 | 2022 | |
| Ascendis Pharma Endocrinology INC | $18.40 | 2025 | Yorvipath |
| Glaxosmithkline, LLC. | $17.93 | 2020 | |
| Sequel Med Tech, LLC | $17.10 | 2025 | Twiist |
| Pfizer INC. | $16.81 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Mohsen Tabrizi listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.